Prostate Reirradiation Toxicity Outcomes Feasibility Study
Launched by UNIVERSITY OF LEEDS · Nov 5, 2022
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The RO-PIP trial is a study looking at treatment options for men with prostate cancer that has come back after previous radiation therapy. The researchers want to see if they can successfully enroll patients in a trial that compares two different types of radiation treatment: one that delivers high doses in fewer sessions and another that uses a special method to place radiation inside the prostate. The goal is to gather information about any side effects patients might experience from these treatments, which will help plan for a larger study in the future.
To qualify for this trial, participants need to be men over 18 years old with a confirmed diagnosis of locally recurrent prostate cancer, meaning the cancer has returned but hasn't spread to other parts of the body. They should also be in good enough health to undergo treatment and have a life expectancy of at least 10 years. Patients will need to provide their consent to join the study and will be monitored for any side effects during the trial. It’s important to note that this trial is not yet open for recruitment, so interested individuals will need to wait until it officially starts.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Male individuals aged over 18 years
- • Histologically confirmed locally recurrent prostate cancer (following previous radiotherapy no less than 2 years ago)
- • No metastatic disease
- • Able and willing to provide an informed consent to participate
- • World Health Organisation (WHO) performance status 0-2
- • Reasonable urinary function (IPSS \< 20 and Qmax \> 10 ml/second on flow tests)
- • Greater than 10 year life expectancy
- Exclusion Criteria:
- • Patients who are unfit for a general anaesthetic due to other comorbidities
- • Clinical or radiological evidence of metastatic prostate disease
- • Any patient with a medical or psychiatric condition that impairs their ability to give informed consent
- • Contraindication or intolerance of magnetic resonance scanning
- • Prior prostatectomy
- • History of inflammatory bowel disease.
About University Of Leeds
The University of Leeds is a prestigious research institution located in the United Kingdom, renowned for its commitment to advancing knowledge through innovative research and education. As a clinical trial sponsor, the University of Leeds leverages its diverse expertise and collaborative environment to facilitate high-quality clinical studies that aim to improve health outcomes and contribute to the scientific community. The university fosters interdisciplinary partnerships, ensuring rigorous methodologies and ethical standards in its research initiatives. By integrating cutting-edge technologies and a patient-centered approach, the University of Leeds plays a vital role in translating research findings into practical applications for healthcare improvement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Ann Henry
Principal Investigator
University of Leeds
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials